These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

843 related articles for article (PubMed ID: 28577748)

  • 61. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.
    Podestà MA; Gennarini A; Portalupi V; Rota S; Alessio MG; Remuzzi G; Ruggenenti P
    Nephron; 2020; 144(1):30-35. PubMed ID: 31336376
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.
    Al-Rabadi L; Ayalon R; Bonegio RG; Ballard JE; Fujii AM; Henderson JM; Salant DJ; Beck LH
    Am J Kidney Dis; 2016 May; 67(5):775-8. PubMed ID: 26744127
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
    Netti GS; Ranieri E
    G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
    Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D
    J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Modern view on treatment of membranous nephropathy].
    Bobkova IN; Kamyshova ES
    Ter Arkh; 2020 Jul; 92(6):99-104. PubMed ID: 33346502
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Treatment resistant M-type phospholipase A2 receptor associated membranous nephropathy responds to obinutuzumab: a report of two cases.
    Hudson R; Rawlings C; Mon SY; Jefferis J; John GT
    BMC Nephrol; 2022 Apr; 23(1):134. PubMed ID: 35392837
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA; Trillini M; Portalupi V; Gennarini A; Tomatis F; Villa A; Perna A; Rubis N; Remuzzi G; Ruggenenti P
    Am J Kidney Dis; 2024 Mar; 83(3):340-349.e1. PubMed ID: 37777061
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Successful Treatment of Patients With Refractory PLA
    Klomjit N; Fervenza FC; Zand L
    Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
    Anjum N; Nabi Z; Alam MA
    J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort.
    Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH
    Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Significance of the total renal chronicity score in predicting renal outcome in PLA2R-associated membranous nephropathy.
    Ren W; Sun J; Zhang L; He W; Guo Z; Bian Q
    J Nephrol; 2024 May; 37(4):1051-1061. PubMed ID: 38512370
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic value of the dynamics of M-type phospholipase A2 receptor antibody titers in patients with idiopathic membranous nephropathy treated with two different immunosuppression regimens.
    Medrano AS; Escalante EJ; Cáceres CC; Pamplona IA; Allende MT; Terrades NR; Carmeno NV; Roldán EO; Agudelo KV; Vasquez JJ
    Biomarkers; 2015 Feb; 20(1):77-83. PubMed ID: 25519165
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy.
    Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE
    Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424
    [TBL] [Abstract][Full Text] [Related]  

  • 75. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
    Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
    Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pregnant woman with primary membranous nephropathy - case report.
    Jankowski J; Jedynak P; Pazik J
    Pol Merkur Lekarski; 2020 Apr; 48(284):105-107. PubMed ID: 32352942
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis.
    Liang Y; Wan J; Chen Y; Pan Y
    BMC Nephrol; 2019 Sep; 20(1):360. PubMed ID: 31533641
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phospholipase A2 Receptor Antibodies and Clinical Prognosis in Patients with Idiopathic Membranous Nephropathy: An Updated Systematic Review and Meta-Analysis.
    Zhang J; Fan Z; Wang P; Zhang AH
    Kidney Blood Press Res; 2023; 48(1):102-113. PubMed ID: 36720217
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Circulating antibodies to α-enolase and phospholipase A
    Kimura Y; Miura N; Debiec H; Morita H; Yamada H; Banno S; Ronco P; Imai H
    Clin Exp Nephrol; 2017 Feb; 21(1):117-126. PubMed ID: 26830547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.